This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
by Kinjel Shah
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
by Zacks Equity Research
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
by Sundeep Ganoria
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
by Kinjel Shah
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle
by Zacks Equity Research
JNJ, HD, MU, AATC, and NVFY stand out with strong gains and strategic shifts amid macro headwinds and evolving consumer demand.
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
by Kanishka Das
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Top Analyst Reports for Johnson & Johnson, Home Depot and Micron
by Mark Vickery
MU gains 42.5% YTD as AI demand fuels DRAM growth, while JNJ and HD navigate pricing, pipeline, and macro headwinds.
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
by Kinjel Shah
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
by Kinjel Shah
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
by Zacks Equity Research
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
by Kinjel Shah
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson
by Zacks Equity Research
Jabil tops Q3 estimates with 35% EPS growth, strong guidance, and momentum from key clients like Apple and Amazon.
Don't Overlook Jabil (JBL) Stock After Topping Its Q3 Expectations
by Shaun Pruitt
Trading near 52-week highs of over $200 a share, Jabil (JBL) stock may be poised for more upside after posting strong results for its fiscal third quarter this week.